What is the net share effect of the Alpha Tau Medical (DRTS) CFO’s Form 4 transactions?

The transaction summary shows a net sale of 17,730 shares , reflecting 17,730 shares sold and no reported open-market purchases beyond the derivative-related acquisition.

Alpha Tau Medical (DRTS) CFO trades 17,730 shares via exercise and sale

Q: What did Alpha Tau Medical (DRTS) CFO Raphi Levy report in this Form 4?

Raphi Levy reported exercising 17,730 Ordinary Shares at $2.98 per share and selling 17,730 shares at $14.0032 per share on 2026-08-11 under a Rule 10b5-1 plan.

Q: How many Alpha Tau Medical (DRTS) shares did the CFO sell?

The CFO sold 17,730 Ordinary Shares of Alpha Tau Medical Ltd. on 2026-08-11 at a reported price of $14.0032 per share , according to the Form 4 filing.

Q: Did the Alpha Tau Medical (DRTS) CFO buy or acquire any shares in this filing?

Yes. Raphi Levy acquired 17,730 Ordinary Shares on 2026-08-11 via an exercise or conversion of a derivative security at $2.98 per share , then sold the same number of shares that day.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Alpha Tau Medical Ltd. Chief Financial Officer Raphi Levy reported two transactions in Ordinary Shares of Alpha Tau Medical Ltd. On 2026-08-11, he acquired 17,730 Ordinary Shares through an exercise or conversion of a derivative security at $2.98 per share, then on the same date sold 17,730 Ordinary Shares at $14.0032 per share. These trades were made pursuant to a Rule 10b5-1 trading plan. The filing does not state his total shareholdings after these transactions.

Insider Trade Summary 10b5-1

2 transactions reported

Mixed 2 txns

Insider Levy Raphi

Role Chief Financial Officer

Sold 17,730 shs ($248K)

Type	Security	Shares	Price	Value
Exercise	Ordinary Shares	17,730	$2.98	$53K
Sale	Ordinary Shares	17,730	$14.0032	$248K

Holdings After Transaction: Ordinary Shares — 90,180 shares (Direct)

Key Figures

Shares acquired via exercise: 17,730 Ordinary Shares Exercise or conversion price: $2.98 per share Shares sold: 17,730 Ordinary Shares +3 more

6 metrics

Shares acquired via exercise 17,730 Ordinary Shares Acquired on 2026-08-11 through exercise or conversion of a derivative security at $2.98 per share

Exercise or conversion price $2.98 per share Price for acquiring 17,730 Ordinary Shares on 2026-08-11

Shares sold 17,730 Ordinary Shares Sold on 2026-08-11 at $14.0032 per share

Sale price $14.0032 per share Price for sale of 17,730 Ordinary Shares on 2026-08-11

Net buy/sell shares -17,730 shares Transaction summary netBuySellShares for reported transactions

Rule 10b5-1 plan status Affirmed aff_10b5_one indicates trades under a Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 trading plan, Ordinary Shares, derivative security

3 terms

Rule 10b5-1 trading plan regulatory

"These trades were made pursuant to a Rule 10b5-1 trading plan."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Ordinary Shares financial

"he acquired 17,730 Ordinary Shares and sold 17,730 Ordinary Shares."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

derivative security financial

"acquired 17,730 Ordinary Shares through an exercise or conversion of a derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

What did Alpha Tau Medical (DRTS) CFO Raphi Levy report in this Form 4?

Raphi Levy reported exercising 17,730 Ordinary Shares at $2.98 per share and selling 17,730 shares at $14.0032 per share on 2026-08-11 under a Rule 10b5-1 plan.

How many Alpha Tau Medical (DRTS) shares did the CFO sell?

The CFO sold 17,730 Ordinary Shares of Alpha Tau Medical Ltd. on 2026-08-11 at a reported price of $14.0032 per share, according to the Form 4 filing.

Did the Alpha Tau Medical (DRTS) CFO buy or acquire any shares in this filing?

Yes. Raphi Levy acquired 17,730 Ordinary Shares on 2026-08-11 via an exercise or conversion of a derivative security at $2.98 per share, then sold the same number of shares that day.

Were the Alpha Tau Medical (DRTS) CFO’s trades made under a Rule 10b5-1 plan?

Yes. The Form 4 indicates the transactions were made under a Rule 10b5-1 trading plan, meaning the trades followed a pre-arranged plan rather than discretionary timing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/12/2026 - 12:19 PM Accepted by SEC EDGAR 08/12/2026 - 12:18 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levy Raphi

(Last)

(First)

(Middle)

C/O ALPHA TAU MEDICAL

PO BOX 45044

(Street)

JERUSALEM

9777605

(City)

(State)

(Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alpha Tau Medical Ltd. [ DRTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	08/11/2026	08/11/2026	M		17,730	A	$2.98	107,910	D
Ordinary Shares	08/11/2026	08/11/2026	S		17,730	D	$14.0032	90,180	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

Remarks:

	Raphi Levy	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR